

Oncology Protocols / February 11, 2010

Site	Number	Protocol Title
Breast	C40101	CALGB Cyclophosphamide and doxorubicin (CA X 4 cycles) versus paclitaxel (4 cycles) as adjuvant therapy for breast cancer in women with 0-3 positive axillary lymph nodes: a Phase III randomized study.
Breast	C40401	CALGB Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following standard adjuvant chemotherapy in early stage, hormone receptor-negative breast cancer.
Breast	C40502	CALGB A randomized Phase III trial of weekly Paclitaxel compared to weekly nanoparticle albumin bound NAB-Paclitaxel or Ixabepilone combined with Bevacizumab as first-line therapy for locally-recurrent or metastatic breast cancer.
Breast	C40503	CALGB Endocrine therapy in combination with anti-VEGF therapy: a randomized, double-blind, placebo-controlled Phase III trial of endocrine therapy alone or endocrine therapy plus bevacizumab (NSC 704865; IND 7921) for women with hormone receptor-positive advanced breast cancer
Breast	E5103	ECOG A double blind Phase III trial of doxorubicin and cyclophosphamide followed by paclitaxel with bevacizumab or placebo in patients with lymph node positive and high risk lymph node negative breast cancer
Breast	IBCSG25- 02	IBCSG Tamoxifen and Exemestane Trial (TEXT). A Phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for <i>premenopausal</i> women with endocrine-responsive breast cancer.
Breast	N063D	NCCTG ALTTO: Adjuvant Lapatinib and / or Trastuzumab Treatment Optimization Study: A randomized, multi-center, open-label, Phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
Breast	N0733	NCCTG Randomized Phase II trial of capecitabine and lapatinib with or without IMC-A12 in patients with HER2 positive breast cancer previously treated with trastuzumab and an anthracycline and / or a taxane
Breast	NSABP B- 43	NSABP A Phase III clinical trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER-2 positive ductal carcinoma in situ resected by lumpectomy.
Breast	PACCT-1	ECOG Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: the TAILORx trial.
Colorectal	C80405	CALGB A Phase III trial of irinotecan / 5-FU / leucovorin with bevacizumab or cetuximab (C225) or with the combination of bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum.
Colorectal	Diagnocure	DIAG-09/002-P Previstage™ GCC for colorectal cancer staging and prognosis
Head and Neck	E1305	ECOG A Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer.
Lung	C30607	CALGB Randomized, Phase III, double-blind, placebo-controlled trial of sunitinib (NSC #736511, IND # 74019) as maintenance therapy in non-progressing patients following an initial four cycles of platinum-based combination chemotherapy in advanced, Stage IIIB / IV non-small cell lung cancer.
Lung NSCLC	C30704	CALGB A randomized Phase II study to assess the efficacy of pemetrexed or sunitinib (NSC #736511, IND #74019) or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer.
Lung NSCLC	E1505	ECOG A Phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected Stage IB (≥4 cm) through IIIA non-small cell lung cancer (NSCLC).
Prostate	BMS CA180227	Bristol-Myers Squibb Protocol CA180227 A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer.
Prostate	RTOG 0534	RTOG A Phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy.
Prostate	S0421	SWOG A Phase III study of docetaxel and atrasentan versus docetaxel and placebo for patients with advanced hormone-refractory prostate cancer.
Renal	E2804	ECOG The BeST Trial: A randomized Phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma. (Clear cell renal cell carcinoma.)
Breast / Prostate / Multiple Myeloma	C70604	CALGB A Randomized Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer.